Clinical Study

Astral - Biogen Brain Contusion Study

Posted Date: Sep 20, 2019

  • Investigator: Laura Ngwenya
  • Specialties: Emergency Medicine, Neurology, Neurosurgery
  • Type of Study: Drug

This is a Biogen-sponsored clinical trial involving 96-hr infusion of study drug or placebo for brain contusion. The study drug is IV Glybenclamide (BIIB093), which is an IV formulation of the oral sulfonylurea anti-diabetic drug, glyburide. Subjects meeting eligibility (including CT scan showing brain contusion) must be randomized within 6 hours of the time of injury, and will receive the 96-hour infusion while admitted to the hospital. Blood glucose will be measured regularly during this time to monitor for potential hypoglycemia. Other study assessments include blood draws, ECGs, and vital signs. Patients are followed acutely until day 7 or discharge from the hospital, and follow-ups will be conducted in person or by phone at day 30, 90, and 180.


Patients With Traumatic Head Injury Causing Brain Contusion, And Less Than 6 Hours From Time Of Injury


Traumatic Brain Injury, Tbi, Glyburide

For More Information:

Hilary Perez

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.